A gene-expression signature defines a subtype of Stomach Adenocarcinomas with low levels of Claudins and a high ratio of NF-YA long/NF-YA short splicing variants - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

A gene expression profile identifies a distinct subtype of Stomach Adenocarcinomas characterized by reduced Claudin levels and an elevated ratio of NF-YA long to NF-YA short splice variants.

  • By

  • Alberto Gallo

  • Mirko Ronzio

  • Maria Barbara Campbell

  • Sofia Polettini

  • Enrico Garattini

  • Roberto Mantovani

  • Diletta Dolfini

  • October 13, 2025

Share

  • 1

    Stomach Adenocarcinoma (STAD) is heterogeneous and has a poor survival rate, classified into various subtypes based on histological and molecular features.

  • 2

    Claudins are proteins involved in cell interactions, with low expression linked to aggressive cancers, including STAD, breast cancer, and bladder cancer.

  • 3

    A distinct Claudinlow subtype in STAD was identified based on a 24-gene transcriptomic signature, indicating unique molecular characteristics.

  • 4

    The NF-Y transcription factor regulates gene expression, with a high NF-YA long/NF-YA short ratio associated with poor clinical outcomes in aggressive cancers.

  • 5

    The study compares gene signatures to refine STAD classification, utilizing RNA-seq data from multiple sources to enhance understanding of tumor subtypes.

Original Source(s)

A gene-expression signature defines a subtype of Stomach Adenocarcinomas with low levels of Claudins and a high ratio of NF-YA long/NF-YA short splicing variants

  • by Alberto Gallo, Mirko Ronzio, Maria Barbara Campbell, Sofia Polettini, Enrico Garattini, Roberto Mantovani, Diletta Dolfini

  • October 13, 2025

Related Content

Assessment of Global Incidence and Risk Factors for Esophageal, Gastric, and Colorectal Cancers in Adolescents and Young Adults: Insights from the 2021 Global Burden of Disease Study

Robot-Assisted Surgery for Gastroesophageal Cancers is Transforming Patient Outcomes

Robot-assisted surgery (RAS) has led to shorter hospital stays, faster recovery and reduced pain for patients with many types of cancer. Now, thanks to the pioneering work of Moshim Kukar, MD, FACS, Department of Surgical Oncology, and his Roswell Park team, RAS is the standard of care for eligible patients with gastroesophageal junction cancers.

  • July 27, 2021

  • 1 min
Retrospective observational cohort study of laparoscopic surgical strategies for gastrointestinal stromal tumors